Ayoub Lahmadi1, Hassan Filali1, Said Elantri1, Hamid Samaki2, Said Lazar1 and Souad Aboudkhil1*
1Laboratory of Biochemistry, Environment and Agri-Food (URAC 36) -Faculty of Sciences and Technology - Mohammedia, Hassan II University, Casablanca, Morocco
2National Institute of Social Action (INAS), Tangier, Morocco
Background: The ubiquitin-proteasome system is an important regulator of cell growth differentiation and apoptosis. Recently proteasome levels have been suggested as a marker of various cancer diseases. In this study, we investigate the involvement of proteasome in skin cancer.
Methods: A mouse model of DMBA induced skin cancer was developed, papilloma or skin tumor confirmed by histopathological analysis. Proteasomes levels were measured using a sandwich ELISA test. The catalytic activity of the 20S proteasome was determined by measuring the fluorescence emitted after the cleavage of AMC.
Results: The results suggested that while all mice in the carcinogenesis group developed tumorlike forms of papilloma, control mice did not show any tumor formation. The histological skin analysis of carcinogenesis mice showed change, illustrated by hyperkeratosis, together with an irregular proliferation, and acanthosis in the epidermis. The serum proteasome and catalytic activity detected in the control group was much lower compared to those obtained in carcinogenesis group. Furthermore, we also noted that a higher level of intracellular proteasome concentration and an important catalytic activity were detected in the carcinogenesis group in comparison to control groups.
Conclusion: The proteasome may represent a novel marker of skin cancer. It could be a key element in the differentiation of normal cells from malignant cells, and may be useful in monitoring the clinical development of malignant cells.
Proteasomes; DMBA-induced skin carcinogenesis; Chymotrypsin-like activity; Skin cancer
Lahmadi A, Filali H, Elantri S, Samaki H, Lazar S, Aboudkhil S. Proteasome: A Novel Potential Biomarker of Skin Cancer in Mouse Model. Clin Oncol. 2021;6:1839..